Table 4

Guidelines for interrupting drotrecogin alfa (activated) infusion for an invasive procedure

Procedurea

Pre-procedure: stop DrotAA

Post-procedure: reconsider DrotAAb


Minor procedure

Arterial line insertion

2 hours before procedure

Immediately afterward

Venous femoral line insertion

2 hours before procedure

Immediately afterward

Re-intubation (tube change)

2 hours before procedure

Immediately afterward

More invasive procedure

Central venous catheter insertion via compressible site (e.g. via femoral vein)

2 hours before procedure

Immediately afterward

Central venous catheter insertion via noncompressible site (e.g. via subclavian or jugular vein)

2 hours before procedure

2 hours afterward

Chest tube insertion or thoracic drainage

2 hours before procedure

2 hours afterward

Gastroscopy (possible biopsy)

2 hours before procedure

2 hours afterward

Lumbar puncture

2 hours before procedure

2 hours afterward

Nephrostomy

2 hours before procedure

2 hours afterward

Paracentesis

2 hours before procedure

2 hours afterward

Percutaneous drainage

2 hours before procedure

2 hours afterward

Sinus puncture

2 hours before procedure

2 hours afterward

Tracheostomy

2 hours before procedure

1 hour afterward

Wound debridement (decubitus ulcer, infected wound, packing changes in open abdomen, etc.)

2 hours before procedure

2 hours afterward

Major procedure

Major surgical procedurec

2 hours before procedure

Wait 12 hours

Epidural catheter

2 hours before procedure; withhold drotrecogin alfa (activated) while catheter present

Wait at least 12 hours after catheter removal before initiating drotrecogin alfa (activated) infusion

Other

CPR

When beginning CPR

Evaluate neurologic status before resuming drotrecogin alfa (activated). If chest trauma occurred, wait 12 hours


aThese guidelines assume that the procedures listed (with the exception of initiation of cardiopulmonary resuscitation [CPR]) are non-emergency. For emergency procedures, the drotrecogin alfa (activated; DrotAA) infusion should be discontinued as soon as possible. The subsequent decision regarding whether and when to reinitiate the infusion depends on the type of procedure and the patient's clinical condition. bIf no signs and symptoms of bleeding are present and the investigator/clinician feels that there is minimal risk for bleeding complications. cA significant surgical procedure that requires the use of an operating room, anesthesia, and so on. DrotAA, drotrecogin alfa (activated). Modified with permission from Laterre and Wittebole [23].

Fumagalli and Mignini Critical Care 2007 11(Suppl 5):S6   doi:10.1186/cc6157